Literature DB >> 15549426

Delayed emesis: moderately emetogenic chemotherapy.

Fausto Roila1, David Warr, Rebecca A Clark-Snow, Maurizio Tonato, Richard J Gralla, Lawrence H Einhorn, Jorn Herrstedt.   

Abstract

Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT(3) antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15549426     DOI： 10.1007/s00520-004-0700-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  19 in total

1.  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

Authors:  R J Gralla; D Osoba; M G Kris; P Kirkbride; P J Hesketh; L W Chinnery; R Clark-Snow; D P Gill; S Groshen; S Grunberg; J M Koeller; G R Morrow; E A Perez; J H Silber; D G Pfister
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

2.  ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV).

Authors: 
Journal:  Ann Oncol       Date:  2001-08       Impact factor: 32.976

Review 3.  ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery.

Authors: 
Journal:  Am J Health Syst Pharm       Date:  1999-04-15       Impact factor: 2.637

4.  Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.

Authors:  G Barrenetxea; J Schneider; M M Centeno; H Romero; M de la Rica; F J Rodríguez-Escudero
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

5.  Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research.

Authors: 
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

6.  The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

Authors:  J L Pater; W S Lofters; B Zee; E Dempsey; D Walde; J P Moquin; K Wilson; P Hoskins; R M Guevin; S Verma; R Navari; J E Krook; J Hainsworth; M Palmer; C Chin
Journal:  Ann Oncol       Date:  1997-02       Impact factor: 32.976

7.  Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy.

Authors:  W H Koo; P T Ang
Journal:  Ann Oncol       Date:  1996-01       Impact factor: 32.976

8.  Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

Authors:  R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro
Journal:  Ann Oncol       Date:  2003-10       Impact factor: 32.976

9.  Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients.

Authors:  A Stewart; B McQuade; J D Cronje; L Goedhals; A Gudgeon; L Corette; X Froger; M Tubiana-Hulin; P Laplaige; J T Roberts
Journal:  Oncology       Date:  1995 May-Jun       Impact factor: 2.935

10.  Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Authors:  Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Hajdenberg; Alan Cartmell; Alberto Macciocchi; Steven Grunberg
Journal:  Cancer       Date:  2003-12-01       Impact factor: 6.860
View more
  15 in total

1.  Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?

Authors:  Terry L Ng; Brian Hutton; Mark Clemons
Journal:  Oncologist       Date:  2015-05-06

2.  Emetic potential of daily oral etoposide.

Authors:  Lawrence H Einhorn; Mary J Brames
Journal:  Support Care Cancer       Date:  2006-08-01       Impact factor: 3.603

3.  5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.

Authors:  Jane T Hickok; Joseph A Roscoe; Gary R Morrow; Christopher W Bole; Hongwei Zhao; Karen L Hoelzer; Shaker R Dakhil; Timothy Moore; Tom R Fitch
Journal:  Lancet Oncol       Date:  2005-09-13       Impact factor: 41.316

4.  An oral history of MASCC, its origin and development from MASCC's beginnings to 2009.

Authors:  Cynthia N Rittenberg; Judith L Johnson; Gerald M Kuncio
Journal:  Support Care Cancer       Date:  2010-03-10       Impact factor: 3.603

5.  Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.

Authors:  Suthinee Ithimakin; Kanakorn Runglodvatana; Akarin Nimmannit; Charuwan Akewanlop; Vichien Srimuninnimit; Narong Keerativitayanan; Nopadol Soparattanapaisarn; Apirom Laocharoenkeat
Journal:  Support Care Cancer       Date:  2011-04-20       Impact factor: 3.603

Review 6.  Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.

Authors:  Rudolph M Navari
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

7.  Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.

Authors:  Maurizio Musso; Renato Scalone; Vincenza Bonanno; Alessandra Crescimanno; Vita Polizzi; Ferdinando Porretto; Carlo Bianchini; Tania Perrone
Journal:  Support Care Cancer       Date:  2008-10-07       Impact factor: 3.603

Review 8.  Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.

Authors:  Rudolph M Navari
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.

Authors:  Rudolph M Navari
Journal:  Cancer Manag Res       Date:  2009-12-10       Impact factor: 3.989

10.  Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.

Authors:  Lijun Tan; Jiangtao Liu; Xiuli Liu; Jie Chen; Zhijun Yan; Huifen Yang; Daxin Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.